Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydroxylase

US2016200703A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016200703-A1
Application numberUS-201414912479-A
CountryUS
Kind codeA1
Filing dateAug 20, 2014
Priority dateAug 20, 2013
Publication dateJul 14, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure is generally directed to compositions and methods for treating diseases that are ameliorated by the inhibition of CYP26 mediated retinoic acid metabolism. The compositions comprise compounds of formula (I). A repreid50000060307390 IB/345 nullsents aryl optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —OH, C 1 -C 6 alkoxy, and C 1 -C 6 haloalkoxy; X is a bond, —CH 2 —, —CHR 5 —, —C═CHR 4 —, —NR 4 —, —N═O—R 4 —, —O—, —S—, —SO—, —SO 2 —, —C(O)—, or —C(NR 4 )—, or X is of formula (a), (b) or (c), wherein each n is independently 1, 2, or 3; each R 4 is independently hydrogen or C 1-6 alkyl; R 5 is independently hydrogen, C 1-6 alkyl, or —OR 6 , where R 6 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyL C 3-12 cycloalkyl, heterocyclyl, aryl, arylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl; Y is C 1-6 alkylene, C 2-6 alkenylene, or C 2-6 alkylylene moiety.

First claim

Opening claim text (preview).

We claim: 1 . A compound of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A represents aryl optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —OH, C 1 -C 6 alkoxy, and C 1 -C 6 haloalkoxy; X is a bond, —CH 2 —, —CHR 5 —, —C═CHR 4 —, —NR 4 —, —N═O—R 4 , —O—, —S—, —SO—, —SO 2 —, —C(O)—, or —C(NR 4 )—, or X is of formula wherein each n is independently 1, 2, or 3; each R 4 is independently hydrogen or C 1-6 alkyl; R 5 is independently hydrogen, C 1-6 alkyl, or —OR 6 , where R 6 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl,C 2-6 alkynyl, C 3-12 cycloalkyl, heterocyclyl, aryl, arylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl; Y is C 1-6 alkylene, C 2-6 alkenylene, or C 2-6 alkylylene moiety; R 1 is C 1-6 alkyl, C 2-6 alkenyl, C 1-6 haloalkyl, C 3-12 cycloalkyl, heterocyclyl, aryl, arylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, —OR 7 , —SR 7 , —N(R 7 ) 2 , —C(O)R 7 , —C(O)OR 7 , —C(O)N(R 7 ) 2 , —S(O) 2 R 7 , —OC(O)R 7 , —OC(O)OR 7 , —OC(O)N(R 7 ) 2 , —N(R 7 )C(O)R 7 , —N(R 7 )C(O)OR 7 , or —N(R 7 )C(O)N(R 7 ) 2 , wherein each R 7 is independently hydrogen or C 1-6 alkyl; R 2 is hydrogen, halogen, C 1-6 alkyl, or —OR 8 , where R 8 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, heterocyclyl, aryl, arylC 1-6 alkyl, heteroaryl, or heteroaryIC 1-6 alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, —OR 7 , —SR 7 , —N(R 7 ) 2 , —C(O)R 7 , —C(O)OR 7 , —C(O)N(R 7 ) 2 , —S(O) 2 R 7 , —OC(O)R 7 , —OC(O)OR 7 , —OC(O)N(R 7 ) 2 , —N(R 7 )C(O)R 7 , —N(R 7 )C(O)OR 7 , or —N(R 7 )C(O)N(R 7 ) 2 , wherein each R 7 is independently hydrogen or C 1-6 alkyl; or R 1 and R 2 together with the atoms to which they are attached form a C 3-12 cycloalkyl, heterocyclyl, aryl, or heteroaryl, each optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, —OR 7 , —SR 7 , —N(R 7 ) 2 , —C(O)R 7 , —C(O)OR 7 , —C(O)N(R 7 ) 2 , —S(O) 2 R 7 , —OC(O)R 7 , —OC(O)OR 7 , —OC(O)N(R 7 ) 2 , —N(R 7 )C(O)R 7 , —N(R 7 )C(O)OR 7 , or —N(R 7 )C(O)N(R 7 ) 2 ; and R 3 is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, —OR, —SR, or —NR 2 , and each R is independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 haloalkyl, C 3-12 cycloalkyl, heterocyclyl, aryl, arylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, —OR 0 , —SR 0 , —N(R 0 ) 2 , —C(O)R 0 , —C(O)OR 0 , —C(O)N(R 0 ) 2 , —S(O) 2 R 0 , —OC(O)R 0 , —OC(O)OR 0 , —OC(O)N(R 0 ) 2 , —N(R 0 )C(O)R 0 , —N(R 0 )C(O)OR 0 , or —N(R 0 )C(O)N(R 0 ) 2 , wherein each R 0 is independently hydrogen or C 1-6 alkyl. 2 . A compound according to claim 1 , wherein A is optionally substituted phenyl having the formula: 3 . A compound according to claim 1 , wherein A is optionally substituted naphthyl having the formula: 4 . A compound according to any one of claims 1 - 3 , wherein X is —CH 2 —, —CHR 5 —, —NR 4 —, —O—, —S—, —SO—, —SO 2 —, —C(O)—, —C(NR 4 )—, or X is of formula wherein each n is independently 1, 2, or 3; each R 4 is independently hydrogen or C 1-6 alkyl; and R 5 is independently hydrogen, C 1-6 alkyl, or —OR 6 , where R 6 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, heterocyclyl, aryl, arylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl. 5 . A compound according to claim 4 , wherein X is —CH 2 —, —CHR 5 —, —NR 4 —, —O—, —S—, —SO—, —SO 2 —, —C(O)—, —C(NR 4 )—, wherein each R 4 is independently hydrogen or C 1-6 alkyl; and R 5 is independently hydrogen, C 1-6 alkyl, or —OR 6 , where R 6 is selected from the group consisting of hydrogen, C 1-5 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, heterocyclyl, aryl, arylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl. 6 . A compound according to claim 4 , wherein X is —CH 2 — or —CHR 5 —, wherein R 5 is independently hydrogen, C 1-6 alkyl, or —OR 6 , where R 6 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, heterocyclyl, aryl, arylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl. 7 . A compound according to claim 6 , wherein X is —CH 2 —. 8 . A compound according to claim 4 , wherein X is —NR 4 2 —, —O—, —S—, —SO—, —SO 2 —, —C(O)—, —C(NR 4 )—, wherein each R 4 is independently hydrogen or C 1-6 alkyl. 9 . A compound according to claim 8 , wherein X is —O—, —S—, —SO—, —SO 2 —, —C(O)—, or —C(NR 4 )—. 10 . A compound according to claim 8 , wherein X is —O—, —S—, —SO—, or —SO 2 —. 11 . A compound according to claim 8 , wherein X is —O—. 12 . A compound according to claim 8 , wherein X is —S—, —SO—, or —SO 2 —. 13 . A compound according to claim 8 , wherein X is —C(O)—. 14 . A compound according to claim 4 , wherein X is of formula and each n is independently 1 or 2. 15 . A compound according to claim 14 , wherein each n is independently 1. 16 . A compound according to any one of claims 1 - 3 wherein X is a bond. 17 . A compound according to any one of claims 1 - 3 , wherein X is a bond, —CH 2 —, —NH—, —S—, —SO 2 , —C(O)—, 18 . A compound according to any one of claims 1 - 3 , wherein X is —CH 2 —, —NH—, —S—, —SO 2 —, —C(O)—, 19 . A compound according to any one of claims 1 - 18 , wherein Y is C 1-6 alkylene or C 2-6 alkenylene. 20 . A compound according to claim 19 , wherein Y is C 1-4 alkylene or C 2-4 alkenylene. 21 . A compound according to claim 19 , wherein Y is C 1-4 alkylene. 22 . A compound according to claim 21 , wherein Y is methylene, ethylene, or propylene. 23 . A compound according to claim 22 , wherein Y is methylene or ethylene. 24 . A compound according to claim 19 , wherein

Assignees

Inventors

Classifications

  • polycyclic · CPC title

  • Ethers · CPC title

  • with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains · CPC title

  • Esters of keto-carboxylic acids {or aldehydo-carboxylic acids} · CPC title

  • Chemistry & Metallurgy · mapped topic

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016200703A1 cover?
The present disclosure is generally directed to compositions and methods for treating diseases that are ameliorated by the inhibition of CYP26 mediated retinoic acid metabolism. The compositions comprise compounds of formula (I). A repreid50000060307390 IB/345 nullsents aryl optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C 1-6 alk…
Who is the assignee on this patent?
Univ Washington Ct Commerciali, Univ Montana
What technology area does this patent fall under?
Primary CPC classification C07D339/06. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Jul 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).